|
1
|
Inokawa Y, Inaoka K, Sonohara F, Hayashi
M, Kanda M and Nomoto S: Molecular alterations in the
carcinogenesis and progression of hepatocellular carcinoma: Tumor
factors and background liver factors. Oncol Lett. 12:3662–3668.
2016.PubMed/NCBI
|
|
2
|
Fernández-Rodríguez CM and
Gutiérrez-García ML: Prevention of hepatocellular carcinoma in
patients with chronic hepatitis B. World J Gastrointest Pharmacol
Ther. 5:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamed O, Kimchi ET, Sehmbey M, Gusani NJ,
Kaifi JT and Staveley-O'Carroll K: Impact of genetic targets on
cancer therapy: Hepatocellular cancer. Adv Exp Med Biol. 779:67–90.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niu ZS, Niu XJ and Wang WH: Genetic
alterations in hepatocellular carcinoma: An update. World J
Gastroenterol. 22:9069–9095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baffy G: Hepatocellular carcinoma in
non-alcoholic fatty liver disease: Epidemiology, pathogenesis and
prevention. J Clin Transl Hepatol. 1:131–137. 2013.PubMed/NCBI
|
|
6
|
de Martel C, Maucort-Boulch D, Plummer M
and Franceschi S: World-wide relative contribution of hepatitis B
and C viruses in hepatocellular carcinoma. Hepatology.
62:1190–1200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakayama H and Takayama T: Management
before hepatectomy for hepatocellular carcinoma with cirrhosis.
World J Hepatol. 7:2292–2302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahdian-Shakib A, Dorostkar R, Tat M,
Hashemzadeh MS and Saidi N: Differential role of microRNAs in
prognosis, diagnosis and therapy of ovarian cancer. Biomed
Pharmacother. 84:592–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shin VY and Chu KM: MiRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krauskopf J, Verheijen M, Kleinjans JC, de
Kok TM and Caiment F: Development and regulatory application of
microRNA biomarkers. Biomark Med. 9:1137–1151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu KW, Fang WL, Huang KH, Huang TT, Lee
HC, Hsieh RH, Chi CW and Yeh TS: Notch1 pathway-mediated
microRNA-151-5p promotes gastric cancer progression. Oncotarget.
7:38036–38051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi RU, Miyazaki H, Takeshita F,
Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M and
Ochiya T: Loss of microRNA-27b contributes to breast cancer stem
cell generation by activating ENPP1. Nat Commun. 6:73182015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li
Y, Li Z, Ng SS, Sung JJ, et al: miR-34a-5p suppresses colorectal
cancer metastasis and predicts recurrence in patients with stage
II/III colorectal cancer. Oncogene. 34:4142–4152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Bryan S, Dong S, Mathis JM and Alahari
SK: The roles of oncogenic miRNAs and their therapeutic importance
in breast cancer. Eur J Cancer. 72:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen B, Pan W, Lin X, Hu Z, Jin Y, Chen H,
Ma G, Qiu Y, Chang L, Hua C, et al: MicroRNA-346 functions as an
oncogene in cutaneous squamous cell carcinoma. Tumour Biol.
37:2765–2771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo J, Lv J, Liu M and Tang H: miR-346
Up-regulates Argonaute 2 (AGO2) protein expression to augment the
activity of other MicroRNAs (miRNAs) and contributes to cervical
cancer cell malignancy. J Biol Chem. 290:30342–30350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu J, Wang S, Zhang W, Qiu J, Shan Y,
Yang D and Shen B: Screening key microRNAs for castration-resistant
prostate cancer based on miRNA/mRNA functional synergistic network.
Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan HL, Li L, Li SJ, Zhang HS and Xu W:
miR-346 promotes migration and invasion of nasopharyngeal carcinoma
cells via targeting BRMS1. J Biochem Mol Toxicol. 30:602–607. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun CC, Li SJ, Yuan ZP and Li DJ:
MicroRNA-346 facilitates cell growth and metastasis, and suppresses
cell apoptosis in human non-small cell lung cancer by regulation of
XPC/ERK/Snail/E-cadherin pathway. Aging (Albany NY). 8:2509–2524.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang F, Luo LJ, Zhang L, Wang DD, Yang SJ,
Ding L, Li J, Chen D, Ma R, Wu JZ and Tang JH: MiR-346 promotes the
biological function of breast cancer cells by targeting SRCIN1 and
reduces chemosensitivity to docetaxel. Gene. 600:21–28. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu X, Cao Y, Zhang J, Lei M, Deng X, Zahid
KR, Liu Y, Liu K, Yang J, Xiong G, et al: Determination of
glutathione in apoptotic SMMC-7221 cells induced by xylitol
selenite using capillary electrophoresis. Biotechnol Lett.
38:761–766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng CW, Wang HW, Chang CW, Chu HW, Chen
CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a
inhibits cell migration and invasion by downregulating vimentin
expression and is a potential prognostic marker in breast cancer.
Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brito AF, Abrantes AM, Tralhão JG and
Botelho MF: Targeting Hepatocellular Carcinoma: What did we
Discover so Far? Oncol Rev. 10:3022016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tornesello ML, Buonaguro L, Izzo F and
Buonaguro FM: Molecular alterations in hepatocellular carcinoma
associated with hepatitis B and hepatitis C infections. Oncotarget.
7:25087–25102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie T, Huang M, Wang Y, Wang L, Chen C and
Chu X: MicroRNAs as regulators, biomarkers and therapeutic targets
in the drug resistance of colorectal cancer. Cell Physiol Biochem.
40:62–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mohammadi A, Mansoori B and Baradaran B:
The role of microRNAs in colorectal cancer. Biomed Pharmacother.
84:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen BB, Coon TA, Glasser JR and
Mallampalli RK: Calmodulin antagonizes a calcium-activated SCF
ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant
homeostasis. Mol Cell Biol. 31:1905–1920. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen BB, Glasser JR, Coon TA and
Mallampalli RK: FBXL2 is a ubiquitin E3 ligase subunit that
triggers mitotic arrest. Cell Cycle. 10:3487–3494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen BB, Glasser JR, Coon TA and
Mallampalli RK: F-box protein FBXL2 exerts human lung tumor
suppressor-like activity by ubiquitin-mediated degradation of
cyclin D3 resulting in cell cycle arrest. Oncogene. 31:2566–2579.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen BB, Glasser JR, Coon TA, Zou C,
Miller HL, Fenton M, McDyer JF, Boyiadzis M and Mallampalli RK:
F-box protein FBXL2 targets cyclin D2 for ubiquitination and
degradation to inhibit leukemic cell proliferation. Blood.
119:3132–3141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li LQ, Pan D, Chen H, Zhang L and Xie WJ:
F-box protein FBXL2 inhibits gastric cancer proliferation by
ubiquitin-mediated degradation of forkhead box M1. FEBS Lett.
590:445–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
